Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: The lesson of the IGHV3-21 gene

Paolo Ghia, Kostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, Stefania Stella, Giuseppe Guida, Ariane Michel, Marta Crespo, Nikolaos Laoutaris, Emili Montserrat, Achilles Anagnostopoulos, Guillaume Dighiero, Athanasios Fassas, Federico Caligaris-Cappio, Frédëric Davi

Research output: Contribution to journalArticle

Abstract

We studied immunoglobulin variable heavy-chain (IGHV) repertoire and mutational status in 553 patients with chronic lymphocytic leukemia (CLL) from the Mediterranean area to gain insight into the potential pathogenetic role of antigenic stimulation. The most commonly represented IGHV genes mirrored the usage of normal B cells, with the exception of IGHV1-18, IGHV3-30.3, and 1GHV4-5G that were underrepresented. The IGHV3-21 gene, frequently expressed in Northern European CLL, was present only in 16 cases (2.9%). Based on HCDR3 cluster analysis, cases using IGHV3-21 could be grouped in 2 subsets of similar frequency. The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL. These cases used the IGHJS gene; 4 of 7 were unmutated; 6 of 7 carried the Vλ2-14 (IGLV3-21) light-chain gene with a similar LCDR3. All expressed CD38 and had a progressive disease. The second subset (9 of 16) was characterized by heterogeneous HCDR3 rearrangements (nonhomogeneous-HCDR3 subset), diverse IGHJ and IGV light-chain gene usage, variable IGHV mutational status (5 of 9 unmutated), variable CD38 expression, and variable clinical course (4 of 9 progressed). The first subset suggests a potential antigenic element rarely encountered in the Mediterranean area, possibly responsible for a negative outcome. The second subset may reflect the physiologic heterogeneity of expression of IGHV3-21 rearrangements in the normal repertoire and is characterized by a variable clinical outcome.

Original languageEnglish
Pages (from-to)1678-1685
Number of pages8
JournalBlood
Volume105
Issue number4
DOIs
Publication statusPublished - Feb 15 2005

Fingerprint

Immunoglobulin Heavy Chain Genes
B-Cell Chronic Lymphocytic Leukemia
Immunoglobulins
Genes
Immunoglobulin Heavy Chains
Light
Cluster Analysis
Cluster analysis
Amino Acid Sequence
B-Lymphocytes
Cells
Amino Acids

ASJC Scopus subject areas

  • Hematology

Cite this

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia : The lesson of the IGHV3-21 gene. / Ghia, Paolo; Stamatopoulos, Kostas; Belessi, Chrysoula; Moreno, Carol; Stella, Stefania; Guida, Giuseppe; Michel, Ariane; Crespo, Marta; Laoutaris, Nikolaos; Montserrat, Emili; Anagnostopoulos, Achilles; Dighiero, Guillaume; Fassas, Athanasios; Caligaris-Cappio, Federico; Davi, Frédëric.

In: Blood, Vol. 105, No. 4, 15.02.2005, p. 1678-1685.

Research output: Contribution to journalArticle

Ghia, P, Stamatopoulos, K, Belessi, C, Moreno, C, Stella, S, Guida, G, Michel, A, Crespo, M, Laoutaris, N, Montserrat, E, Anagnostopoulos, A, Dighiero, G, Fassas, A, Caligaris-Cappio, F & Davi, F 2005, 'Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: The lesson of the IGHV3-21 gene', Blood, vol. 105, no. 4, pp. 1678-1685. https://doi.org/10.1182/blood-2004-07-2606
Ghia, Paolo ; Stamatopoulos, Kostas ; Belessi, Chrysoula ; Moreno, Carol ; Stella, Stefania ; Guida, Giuseppe ; Michel, Ariane ; Crespo, Marta ; Laoutaris, Nikolaos ; Montserrat, Emili ; Anagnostopoulos, Achilles ; Dighiero, Guillaume ; Fassas, Athanasios ; Caligaris-Cappio, Federico ; Davi, Frédëric. / Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia : The lesson of the IGHV3-21 gene. In: Blood. 2005 ; Vol. 105, No. 4. pp. 1678-1685.
@article{738950044bfa46c1a100f84eb3ab21c7,
title = "Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: The lesson of the IGHV3-21 gene",
abstract = "We studied immunoglobulin variable heavy-chain (IGHV) repertoire and mutational status in 553 patients with chronic lymphocytic leukemia (CLL) from the Mediterranean area to gain insight into the potential pathogenetic role of antigenic stimulation. The most commonly represented IGHV genes mirrored the usage of normal B cells, with the exception of IGHV1-18, IGHV3-30.3, and 1GHV4-5G that were underrepresented. The IGHV3-21 gene, frequently expressed in Northern European CLL, was present only in 16 cases (2.9{\%}). Based on HCDR3 cluster analysis, cases using IGHV3-21 could be grouped in 2 subsets of similar frequency. The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL. These cases used the IGHJS gene; 4 of 7 were unmutated; 6 of 7 carried the Vλ2-14 (IGLV3-21) light-chain gene with a similar LCDR3. All expressed CD38 and had a progressive disease. The second subset (9 of 16) was characterized by heterogeneous HCDR3 rearrangements (nonhomogeneous-HCDR3 subset), diverse IGHJ and IGV light-chain gene usage, variable IGHV mutational status (5 of 9 unmutated), variable CD38 expression, and variable clinical course (4 of 9 progressed). The first subset suggests a potential antigenic element rarely encountered in the Mediterranean area, possibly responsible for a negative outcome. The second subset may reflect the physiologic heterogeneity of expression of IGHV3-21 rearrangements in the normal repertoire and is characterized by a variable clinical outcome.",
author = "Paolo Ghia and Kostas Stamatopoulos and Chrysoula Belessi and Carol Moreno and Stefania Stella and Giuseppe Guida and Ariane Michel and Marta Crespo and Nikolaos Laoutaris and Emili Montserrat and Achilles Anagnostopoulos and Guillaume Dighiero and Athanasios Fassas and Federico Caligaris-Cappio and Fr{\'e}d{\"e}ric Davi",
year = "2005",
month = "2",
day = "15",
doi = "10.1182/blood-2004-07-2606",
language = "English",
volume = "105",
pages = "1678--1685",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia

T2 - The lesson of the IGHV3-21 gene

AU - Ghia, Paolo

AU - Stamatopoulos, Kostas

AU - Belessi, Chrysoula

AU - Moreno, Carol

AU - Stella, Stefania

AU - Guida, Giuseppe

AU - Michel, Ariane

AU - Crespo, Marta

AU - Laoutaris, Nikolaos

AU - Montserrat, Emili

AU - Anagnostopoulos, Achilles

AU - Dighiero, Guillaume

AU - Fassas, Athanasios

AU - Caligaris-Cappio, Federico

AU - Davi, Frédëric

PY - 2005/2/15

Y1 - 2005/2/15

N2 - We studied immunoglobulin variable heavy-chain (IGHV) repertoire and mutational status in 553 patients with chronic lymphocytic leukemia (CLL) from the Mediterranean area to gain insight into the potential pathogenetic role of antigenic stimulation. The most commonly represented IGHV genes mirrored the usage of normal B cells, with the exception of IGHV1-18, IGHV3-30.3, and 1GHV4-5G that were underrepresented. The IGHV3-21 gene, frequently expressed in Northern European CLL, was present only in 16 cases (2.9%). Based on HCDR3 cluster analysis, cases using IGHV3-21 could be grouped in 2 subsets of similar frequency. The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL. These cases used the IGHJS gene; 4 of 7 were unmutated; 6 of 7 carried the Vλ2-14 (IGLV3-21) light-chain gene with a similar LCDR3. All expressed CD38 and had a progressive disease. The second subset (9 of 16) was characterized by heterogeneous HCDR3 rearrangements (nonhomogeneous-HCDR3 subset), diverse IGHJ and IGV light-chain gene usage, variable IGHV mutational status (5 of 9 unmutated), variable CD38 expression, and variable clinical course (4 of 9 progressed). The first subset suggests a potential antigenic element rarely encountered in the Mediterranean area, possibly responsible for a negative outcome. The second subset may reflect the physiologic heterogeneity of expression of IGHV3-21 rearrangements in the normal repertoire and is characterized by a variable clinical outcome.

AB - We studied immunoglobulin variable heavy-chain (IGHV) repertoire and mutational status in 553 patients with chronic lymphocytic leukemia (CLL) from the Mediterranean area to gain insight into the potential pathogenetic role of antigenic stimulation. The most commonly represented IGHV genes mirrored the usage of normal B cells, with the exception of IGHV1-18, IGHV3-30.3, and 1GHV4-5G that were underrepresented. The IGHV3-21 gene, frequently expressed in Northern European CLL, was present only in 16 cases (2.9%). Based on HCDR3 cluster analysis, cases using IGHV3-21 could be grouped in 2 subsets of similar frequency. The first one (7 of 16 cases) carried a similar HCDR3 amino acid sequence (common-HCDR3 subset), virtually identical to the Scandinavian IGHV3-21 CLL. These cases used the IGHJS gene; 4 of 7 were unmutated; 6 of 7 carried the Vλ2-14 (IGLV3-21) light-chain gene with a similar LCDR3. All expressed CD38 and had a progressive disease. The second subset (9 of 16) was characterized by heterogeneous HCDR3 rearrangements (nonhomogeneous-HCDR3 subset), diverse IGHJ and IGV light-chain gene usage, variable IGHV mutational status (5 of 9 unmutated), variable CD38 expression, and variable clinical course (4 of 9 progressed). The first subset suggests a potential antigenic element rarely encountered in the Mediterranean area, possibly responsible for a negative outcome. The second subset may reflect the physiologic heterogeneity of expression of IGHV3-21 rearrangements in the normal repertoire and is characterized by a variable clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=13544275555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544275555&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-07-2606

DO - 10.1182/blood-2004-07-2606

M3 - Article

C2 - 15466924

AN - SCOPUS:13544275555

VL - 105

SP - 1678

EP - 1685

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -